This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

### Market Applicability

<table>
<thead>
<tr>
<th>Market</th>
<th>DC</th>
<th>GA</th>
<th>KY</th>
<th>MD</th>
<th>NJ</th>
<th>NY</th>
<th>WA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicable</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>NA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Dosage</th>
<th>Usage</th>
<th>Market Access</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lupron Depot Ped (3 month) (leuprolide acetate) 11.25mg</td>
<td>1 kit per 12 weeks</td>
<td>VA MCD and AGP MCD Only</td>
<td></td>
</tr>
<tr>
<td>Lupron Depot Ped (3 month) (leuprolide acetate) 30mg</td>
<td>N/A</td>
<td>VA MCD and AGP MCD Only</td>
<td></td>
</tr>
<tr>
<td>Supprelin LA (histrelin acetate) 50mg</td>
<td>1 implant per year</td>
<td>VA MCD and AGP MCD Only</td>
<td></td>
</tr>
<tr>
<td>Synarel Nasal Spray (nafarelin acetate) 2mg/mL (60 sprays/bottle)</td>
<td>5 bottles per 30 days</td>
<td>All MCD</td>
<td></td>
</tr>
<tr>
<td>Trelstar (triptorelin pamoate) 22.5mg</td>
<td>1 per 24 weeks</td>
<td>VA MCD and AGP MCD Only</td>
<td></td>
</tr>
<tr>
<td>Trelstar Depot (triptorelin pamoate) 3.75mg</td>
<td>1 per 4 weeks</td>
<td>VA MCD and AGP MCD Only</td>
<td></td>
</tr>
<tr>
<td>Trelstar LA (triptorelin pamoate) 11.25mg</td>
<td>1 per 12 weeks</td>
<td>VA MCD and AGP MCD Only</td>
<td></td>
</tr>
<tr>
<td>Triptodur (triptorelin pamoate extended release) 22.5mg kit</td>
<td>1 kit per 24 weeks</td>
<td>VA MCD and AGP MCD Only</td>
<td></td>
</tr>
<tr>
<td>Vantas Implant (histrelin acetate)</td>
<td>N/A</td>
<td>VA MCD and AGP MCD Only</td>
<td></td>
</tr>
<tr>
<td>Zoladex (1 month) (goserelin acetate) 3.6mg implant</td>
<td>1 per 4 weeks</td>
<td>VA MCD and AGP MCD Only</td>
<td></td>
</tr>
<tr>
<td>Zoladex (3 month) (goserelin acetate) 10.8mg implant</td>
<td>1 per 12 weeks</td>
<td>VA MCD and AGP MCD Only</td>
<td></td>
</tr>
</tbody>
</table>

### APPROVAL CRITERIA

I. **Breast Cancer – Goserelin acetate or leuprolide acetate (Lupron Depot 3.75 mg)**

Goserelin acetate or leuprolide acetate (Lupron Depot 3.75 mg) **may be approved** for the treatment of men and pre- or peri-menopausal women with hormone receptor positive breast cancer.

Goserelin acetate or leuprolide acetate **may NOT be approved** for the treatment of breast cancer when the criteria above are not met.

II. **Ovarian Cancer (including fallopian tube cancer and primary peritoneal cancer) – Leuprolide acetate (Lupron Depot 3.75 mg, Lupron Depot-3 Month 11.25 mg)**
Leuprolide acetate (Lupron Depot 3.75 mg, Lupron Depot-3 Month 11.25 mg) may be approved for ovarian cancer when any of the following are met:
   A. Hormonal therapy for clinical relapse in individuals with stage II-IV granulosa cell tumors; OR
   B. Hormonal therapy for treatment of epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer as a single agent for persistent disease or recurrence.

Leuprolide acetate may NOT be approved for ovarian cancer when the criteria above are not met.

III. Prostate Cancer- Degarelix; goserelin acetate; histrelin acetate (Vantas); leuprolide acetate (Eligard 7.5 mg [1 Month], 22.5 mg [3 Month], 30 mg [4 month], 45 mg [6 Month]; Lupron Depot 7.5 mg [1 Month], 22.5 mg [3 Month], 30 mg [4 Month], 45 mg [6 Month]), or triptorelin pamoate

   A. Degarelix; goserelin acetate; histrelin acetate (Vantas); leuprolide acetate, or (Eligard 7.5 mg [1 Month], 22.5 mg [3 Month], 30 mg [4 Month], 45 mg [6 Month]; Lupron Depot 7.5 mg [1 Month], 22.5 mg [3 Month], 30 mg [4 Month], 45 mg [6 Month]); triptorelin pamoate may be approved for the treatment of prostate cancer when any of the following indications are met:
      1. Used as androgen deprivation therapy as a single agent or in combination with an antiandrogen; OR
      2. Used for clinically localized disease* with intermediate (T2b to T2c cancer, Gleason score of 7/Gleason grade group 2-3, or prostate specific antigen (PSA) value of 10-20 ng/ml) or higher risk of recurrence as neoadjuvant therapy with radiation therapy or cryosurgery; OR
      3. Used for progressive castration-naïve disease; OR
      4. Used for castration-recurrent disease; OR
      5. Other advanced*, recurrent, or metastatic disease*.

*Definitions—
   • Clinically localized prostate cancer: Cancer presumed to be confined within the prostate based on pre-treatment findings such as physical exam, imaging, and biopsy findings.
   • Locally advanced disease (prostate cancer): Cancer that has spread from where it started to nearby tissue or lymph nodes.
Market Applicability

<table>
<thead>
<tr>
<th>Market</th>
<th>DC</th>
<th>GA</th>
<th>KY</th>
<th>MD</th>
<th>NJ</th>
<th>NY</th>
<th>WA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicable</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>NA</td>
</tr>
</tbody>
</table>

- Metastatic: The spread of cancer from one part of the body to another; a metastatic tumor contains cells that are like those in the original (primary) tumor and have spread.
- Advanced prostate cancer: Disease that has spread beyond the prostate to surrounding tissues or distant organs.

Degarelix, goserelin acetate, histrelin acetate (Vantas), leuprolide acetate, or triptorelin pamoate may **NOT be approved for** treatment of prostate cancer when the criteria above are not met.

**IV. Central Precocious Puberty- Leuprolide acetate (Lupron Depot-Ped), nafarelin acetate (Synarel Nasal Spray), histrelin acetate subcutaneous implant (Supprelin LA), triptorelin pamoate intramuscular extended release (Triptodur)**

A. Leuprolide acetate (Lupron Depot-Ped), nafarelin acetate (Synarel Nasal Spray), histrelin acetate subcutaneous implant (Supprelin LA), and triptorelin IM (Triptodur) **may be approved** for individuals with a diagnosis of central precocious puberty (defined as the beginning of secondary sexual characteristics before age 8 in girls and 9 in boys) (Kaplowitz, et al. 2016); **AND**

B. If individual is using Triptodur (triptorelin pamoate), IM injection is given every 6 months for those 2 years of age or older.

**V. Gynecology Uses- Goserelin acetate, leuprolide acetate, leuprolide acetate for depot suspension and norethindrone (Lupaneta Pack), or nafarelin acetate**

A. Goserelin acetate, leuprolide acetate, or nafarelin acetate **may be approved** the following criteria are met:

1. Individual has a diagnosis of chronic pelvic pain* (defined as noncyclical pain lasting 6 or more months that localizes to the anatomic pelvis, anterior abdominal wall at or below the umbilicus, the lumbosacral back, or the buttocks, and is of sufficient severity to cause functional disability or lead to medical care [ACOG, 2004])-*not to continue beyond 3 months if there is no symptomatic relief; **OR**

2. Individual is using to induce amenorrhea (including, but not limited to menstruating women diagnosed with severe thrombocytopenia or aplastic anemia).

B. Goserelin acetate **may be approved** if the following criteria are met:

1. Individual is using for treatment of endometriosis and duration of treatment limited to 6 months; **OR**

---

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
2. Individual is using for dysfunctional uterine bleeding; OR
3. Individual is using for endometrial thinning prior to endometrial ablation for dysfunctional uterine bleeding (3.6 mg implant only).

C. Leuprolide acetate may be approved if the following criteria are met:
   1. Individual is using for initial treatment or retreatment of endometriosis (Initial treatment duration: 6 months; Retreatment duration: a single course for 6 months. Total duration of therapy should not exceed 12 months); OR
   2. Individual is using for preoperative treatment as adjunct to surgical treatment of uterine fibroids (leiomyoma uteri), including but not limited to reducing the size of fibroids to allow for a vaginal procedure (AHFS); OR
   3. Individual is using prior to surgical treatment (myomectomy or hysterectomy) in those with a diagnosis of confirmed anemia (Letheby et.al. 2001).

D. Leuprolide acetate for depot suspension and norethindrone acetate tablets (Lupaneta Pack) may be approved if the following criteria are met:
   1. Individual is using for initial treatment or retreatment of endometriosis (Initial treatment duration: 6 months; Retreatment duration: a single course for 6 months. Total duration of therapy should not exceed 12 months).

E. Nafarelin acetate may be approved if the following criteria are met:
   1. Individual is using for endometriosis; AND
   2. Duration of treatment limited to 6 months.

VI. Ovarian Preservation for Fertility during Chemotherapy

A. GnRH analogs may be approved for preservation of fertility in pre-menopausal women that will receive chemotherapy with curative intent.

GnRH analogs may NOT be approved for preservation of fertility when the criteria above are not met.

VII. Gender Dysphoria/Incongruence in Adolescents

A. GnRH analogs may be approved for adolescents (greater than or equal to 10 years of age and less than 18 years of age) with gender dysphoria (Hembree 2009, 2017) when all of the following criteria are met:

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
1. Fulfills the DSM V criteria for gender dysphoria (Hembree 2009, 2017); AND
2. Has experienced puberty to at least Tanner stage 2 (Hembree 2009, 2017); AND
3. Has (early) pubertal changes that have resulted in an increase of their gender dysphoria (Hembree 2009, 2017); AND
4. Does not suffer from a psychiatric comorbidity that interferes with the diagnostic work-up or treatment (Hembree 2009, 2017); AND
5. Has psychological and social support during treatment (Hembree 2009, 2017); AND

GnRH analogs may NOT be approved for adolescents with gender dysphoria when the criteria above are not met.

VIII. Salivary Gland Tumors – Leuprolide acetate (Eligard 7.5 mg [1 Month], 22.5 mg [3 Month]; Lupron Depot 7.5 mg [1 Month], 22.5 mg [3 Month])

   A. Leuprolide acetate (Eligard 7.5 mg [1 Month], 22.5 mg [3 Month]; Lupron Depot 7.5 mg [1 Month], 22.5 mg [3 Month]) may be approved for the treatment of salivary gland tumors when all of the following criteria are met:
      1. Used for androgen receptor positive recurrent disease with distant metastases; AND
      2. Individual has a current Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-3.

   Leuprolide acetate may NOT be approved for the treatment of salivary gland tumors when the criteria above are not met.

Key References:


This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
27. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
32. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.